ArticleProceedings of the National Academy of Sciences of the United States of America2004
Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside).
Article in Proceedings of the National Academy of Sciences of the United States of America, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 70 citations in OpenAlex.
- Ganglioside GM3 in the Tumor Microenvironment: Mechanisms of Signaling Regulation and Strategies for Angiogenesis Inhibition.Biomolecules · 2026Review
- Structure and function of glycosphingolipids on small extracellular vesicles.Glycoconjugate journal · 2022Review
- Sphingolipid metabolism in the development and progression of cancer: one cancer's help is another's hindrance.Molecular oncology · 2021Review
- Tumor reversion: a dream or a reality.Biomarker research · 2021Review
- Glycosphingolipids.Advances in experimental medicine and biology · 2021Article
- Comprehensive Profiling of Surface Gangliosides Extracted from Various Cell Lines by LC-MS/MS.Cells · 2019Article
- Gangliosides profiling in serum of breast cancer patient: GM3 as a potential diagnostic biomarker.Glycoconjugate journal · 2019Article
- Induction of Glycosphingolipid GM3 Expression by Valproic Acid Suppresses Cancer Cell Growth.The Journal of biological chemistry · 2016Article
- GM3 and cancer.Glycoconjugate journal · 2015Review
- Reduced GM1 ganglioside in CFTR-deficient human airway cells results in decreased β1-integrin signaling and delayed wound repair.American journal of physiology. Cell physiology · 2014Article
- A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells.Glycoconjugate journal · 2013Article
- Self-recognition of high-mannose type glycans mediating adhesion of embryonal fibroblasts.Glycoconjugate journal · 2013Article
- Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Glycosylation effects on cancer development.Glycoconjugate journal · 2012Article
- Sialidase significance for cancer progression.Glycoconjugate journal · 2012Review
- Induction of epithelial-mesenchymal transition with O-glycosylated oncofetal fibronectin.FEBS letters · 2012Article
- A glycosphingolipid/caveolin-1 signaling complex inhibits motility of human ovarian carcinoma cells.The Journal of biological chemistry · 2011Article
- Protein expression profiles of C3H 10T1/2 murine fibroblasts and of isogenic cells transformed by the H1047R mutant of phosphoinositide 3-kinase (PI3K).Cell cycle (Georgetown, Tex.) · 2011Article
- Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility.FEBS letters · 2010Review
- Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression.Molecular oncology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
In the mouse fibroblast cell line C3H 10T1/2 and the chicken fibroblast cell line DF1, the ganglioside GM3 is the major glycosphingolipid component of the plasma membrane. Expression of the viral oncoprotein Jun (v-Jun) induces transformed cell clones with greatly reduced levels of GM3 and GM3 synthase (lactosylceramide alpha2,3-sialyltransferase) mRNA in both 10T1/2 and DF1 cell cultures. Compared with nontransformed controls, v-Jun transfectants show enhanced ability of anchorage-independent growth, and their growth rates as adherent cells are increased. When the mouse GM3 synthase gene is transfected with the pcDNA vector into v-Jun-transformed 10T1/2 cells, the levels of GM3 synthase and corresponding mRNA are restored to those of control cells. Reexpression of GM3 correlates with a reduced ability of the cells to form colonies in nutrient agar. Similarly, when the newly cloned chicken GM3 synthase gene is transfected into v-Jun-transformed DF1 with the pcDNA vector, the GM3 synthase level is restored to that of control cells, and the ability of the cells to form agar colonies is reduced. The levels of GM3 in the cell also affect membrane microdomains. The complex of GM3 with tetraspanin CD9 and integrin alpha5beta1 inhibits motility and invasiveness. The amounts of this complex are greatly reduced in transformed cells. Expression of GM3 and consequent reversion of the transformed phenotype results in increased levels of that microdomain complex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.